336 related articles for article (PubMed ID: 34057709)
41. Nociceptin/orphanin FQ: actions within the brain.
Meis S
Neuroscientist; 2003 Apr; 9(2):158-68. PubMed ID: 12708619
[TBL] [Abstract][Full Text] [Related]
42. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
Tzschentke TM; Rutten K
Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and biological activity of small peptides as NOP and opioid receptors' ligands: view on current developments.
Naydenova E; Todorov P; Zamfirova R
Vitam Horm; 2015; 97():123-46. PubMed ID: 25677770
[TBL] [Abstract][Full Text] [Related]
44. NOP Receptor Signaling Cascades.
Parker KE; Bruchas MR
Handb Exp Pharmacol; 2019; 254():131-139. PubMed ID: 31087192
[TBL] [Abstract][Full Text] [Related]
45. Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats.
Micheli L; Di Cesare Mannelli L; Guerrini R; Trapella C; Zanardelli M; Ciccocioppo R; Rizzi A; Ghelardini C; Calò G
Eur J Pharmacol; 2015 May; 754():73-81. PubMed ID: 25704616
[TBL] [Abstract][Full Text] [Related]
46. [3H]-nociceptin ligand-binding and nociceptin opioid receptor mrna expression in the human brain.
Berthele A; Platzer S; Dworzak D; Schadrack J; Mahal B; Büttner A; Assmus HP; Wurster K; Zieglgänsberger W; Conrad B; Tölle TR
Neuroscience; 2003; 121(3):629-40. PubMed ID: 14568023
[TBL] [Abstract][Full Text] [Related]
47. NOP-Related Mechanisms in Substance Use Disorders.
Ciccocioppo R; Borruto AM; Domi A; Teshima K; Cannella N; Weiss F
Handb Exp Pharmacol; 2019; 254():187-212. PubMed ID: 30968214
[TBL] [Abstract][Full Text] [Related]
48. Comparative biochemical and pharmacological characterization of a novel, NOP receptor selective hexapeptide, Ac-RYYRIR-ol.
Bojnik E; Babos F; Fischetti C; Magyar A; Camarda V; Borsodi A; Bajusz S; Calo' G; Benyhe S
Brain Res Bull; 2010 Mar; 81(4-5):477-83. PubMed ID: 19800951
[TBL] [Abstract][Full Text] [Related]
49. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
[TBL] [Abstract][Full Text] [Related]
50. N/OFQ-NOP System in Food Intake.
Micioni Di Bonaventura MV; Micioni Di Bonaventura E; Cifani C; Polidori C
Handb Exp Pharmacol; 2019; 254():279-295. PubMed ID: 31073870
[TBL] [Abstract][Full Text] [Related]
51. Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).
Bird MF; Cerlesi MC; Brown M; Malfacini D; Vezzi V; Molinari P; Micheli L; Di Cesare Mannelli L; Ghelardini C; Guerrini R; Calò G; Lambert DG
PLoS One; 2016; 11(6):e0156897. PubMed ID: 27272042
[TBL] [Abstract][Full Text] [Related]
52. [Therapeutic potentials of safe opioid analgesics targeting nociceptin/orphanin FQ peptide receptor].
Kiguchi N; Kishioka S; Ko MC
Nihon Yakurigaku Zasshi; 2021; 156(3):139-144. PubMed ID: 33952840
[TBL] [Abstract][Full Text] [Related]
53. Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex.
Mela F; Marti M; Ulazzi L; Vaccari E; Zucchini S; Trapella C; Salvadori S; Beani L; Bianchi C; Morari M
Eur J Neurosci; 2004 Mar; 19(5):1317-24. PubMed ID: 15016089
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse.
Kiguchi N; Ding H; Ko MC
J Neurosci Res; 2022 Jan; 100(1):191-202. PubMed ID: 32255240
[TBL] [Abstract][Full Text] [Related]
55. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.
Lin AP; Ko MC
ACS Chem Neurosci; 2013 Feb; 4(2):214-24. PubMed ID: 23421672
[TBL] [Abstract][Full Text] [Related]
56. UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.
Calo' G; Rizzi A; Cifani C; Micioni Di Bonaventura MV; Regoli D; Massi M; Salvadori S; Lambert DG; Guerrini R
CNS Neurosci Ther; 2011 Jun; 17(3):178-98. PubMed ID: 20497197
[TBL] [Abstract][Full Text] [Related]
57. Chronic high-NaCl intake prolongs the cardiorenal responses to central N/OFQ and produces regional changes in the endogenous brain NOP receptor system.
Wainford RD; Kapusta DR
Am J Physiol Regul Integr Comp Physiol; 2009 Feb; 296(2):R280-8. PubMed ID: 18987291
[TBL] [Abstract][Full Text] [Related]
58. Differential In Vitro Pharmacological Profiles of Structurally Diverse Nociceptin Receptor Agonists in Activating G Protein and Beta-Arrestin Signaling at the Human Nociceptin Opioid Receptor.
Lu JJ; Polgar WE; Mann A; Dasgupta P; Schulz S; Zaveri NT
Mol Pharmacol; 2021 Jul; 100(1):7-18. PubMed ID: 33958480
[TBL] [Abstract][Full Text] [Related]
59. Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.
Schröder W; Lambert DG; Ko MC; Koch T
Br J Pharmacol; 2014 Aug; 171(16):3777-800. PubMed ID: 24762001
[TBL] [Abstract][Full Text] [Related]
60. Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.
Ciccocioppo R; Economidou D; Rimondini R; Sommer W; Massi M; Heilig M
Biol Psychiatry; 2007 Jan; 61(1):4-12. PubMed ID: 16533497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
